Abstract: Aspects of the present disclosure are directed to methods for treating a subject having cancer. Certain aspects relate to treating a subject for lung cancer by administering poziotinib to a subject determined, from analysis of tumor DNA from the subject, to have an EGFR mutation of a particular classification. Further aspects relate to methods for treating a subject for lung cancer by detecting an EGFR mutation of a particular classification in tumor DNA from the subject and administering an effective amount of poziotinib to the subject. Also disclosed are methods for stratifying and prognosing subjects based on EGFR mutation classification.

Abstract: Provided herein are methods for determining a subtype of a small cell lung cancer in a patient based on the express status of ASCL1, NEUROD1, and POU2F3, which are expressed in a mutually exclusive fashion. The subtype of the cancer can be used to determine the sensitivity of the cancer to certain anti-cancer therapies. As such, also provided are methods of treating patients having small cell lung cancer based on the subtyping results.

Abstract: Aspects of the present disclosure are directed to methods for classification and treatment of small cell lung cancer (SCLC). Certain aspects pertain to treatment of a subject having SCLC using a targeting agent for a cell surface protein, where a targeting agent is selected based on a subtype classification of the SCLC. Disclosed are methods for identifying a subject as having an SCLC subtype (e.g., SCLC-A, SCLC-N, SCLC-P, SCLC-I) and administering a targeting agent configured to target a cell surface protein associated with the identified SCLC subtype. Also disclosed are compositions comprising targeting agents for treatment of SCLC.

Abstract: Provided herein are methods for determining a subtype of a small cell lung cancer in a patient based on the express status of ASCL1, NEUROD1, and POU2F3, which are expressed in a mutually exclusive fashion. The subtype of the cancer can be used to determine the sensitivity of the cancer to certain anti-cancer therapies. As such, also provided are methods of treating patients having small cell lung cancer based on the subtyping results.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have a p53 mutation by administering an inhibitor of nonsense mediated decay. The patient may be further administered an inhibitor of mRNA splicing and/or an inhibitor of MDM.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.

Abstract: Aspects of the disclosure relate to a method for treating EGFR-mutant non-small-cell lung cancer (NSCLC) in a patient comprising administering a CD70 targeting molecule to the patient. Further aspects of the disclosure relate to a method for treating an epithelial-to-mesenchymal transition (EMT)-positive NSCLC in a patient comprising administering a CD70-targeting molecule to the patient.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have osimertinib resistant EGFR mutations by administering a second-generation quinazolinamine derivative tyrosine kinase inhibitor.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an HER2 exon 21 mutation by administering a third-generation tyrosine kinase inhibitor, such as poziotinib.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have osimertinib resistant EGFR mutations by administering a third-generation tyrosine kinase inhibitor, such as poziotinib.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have a HER2 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib, in combination with a HER2 anti-body-drug conjugate.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have a HER2 exon 19 mutation, such as a point mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib.

Abstract: Provided herein are methods for determining a subtype of a small cell lung cancer in a patient based on the express status of ASCL1, NEUROD1, and POU2F3, which are expressed in a mutually exclusive fashion. The subtype of the cancer can be used to determine the sensitivity of the cancer to certain anti-cancer therapies. As such, also provided are methods of treating patients having small cell lung cancer based on the subtyping results.

Abstract: The present disclosure provides methods for treating cancer in a patient determined to have an EGFR activating mutation by administering a CDK inhibitor and/or SAC component inhibitor.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.

Abstract: EMT signatures and markers useful for characterizing the status of epithelial cancers and for predicting drug responses in patients having non-small cell lung cancer are provided together with methods of using the same.